Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple separate lung cancers (confirmed by both clinical assessment and tissue testing)
• People who had 3 or more lung nodules at the time of their first diagnosis or before surgery, with no spread to the lymph nodes
• People whose largest lung nodule measures 3 cm (about 1.2 inches) or less across
• People who have already had surgery to remove at least one nodule, with 2 or more nodules still remaining, and where post-surgery testing confirmed those remaining nodules are a very early, minimally invasive type of cancer (MIA or AIS)
• People who are expected to have at least 1 measurable nodule remaining after a freezing treatment (cryotherapy), based on standard measurement guidelines
• People aged 18 to 75 years old, of any gender
• People who are generally well enough to carry out daily activities with little or no limitation, based on a standard health scoring system (ECOG score of 0 or 1)
• People whose life expectancy is estimated to be at least 12 weeks
• People whose blood counts, liver, and kidney function meet specific healthy ranges as tested by blood tests (confirm with trial site for exact values)
• People who are willing and able to use an approved form of contraception during treatment and for 6 months after treatment ends (if applicable)
• People who are able to give written consent and follow the trial's visit schedule and procedures

Who may not be able to join:

• People whose cancer has specific genetic changes known as EGFR mutations or ALK rearrangements
• People whose cancer cannot safely be treated with cryotherapy — for example, nodules spread widely through both lungs, extensive spread to the lining of the lungs with large fluid build-up, or tumours growing around major blood vessels in the chest
• People who have previously been treated with certain immune-based therapies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 drugs, or similar treatments that affect immune system checkpoints
• People who received chemotherapy, targeted therapy, immunotherapy, or any experimental drug within 4 weeks before joining the trial
• People who received high-dose steroid medications (above a certain daily threshold) within the 4 weeks before joining
• People who had major surgery within the 4 weeks before joining, or who have wounds, ulcers, or fractures that have not yet healed
• People with a known or suspected active autoimmune condition (a condition where the immune system attacks the body's own tissues)
• People who have had an organ transplant (other than a corneal transplant) or a bone marrow/stem cell transplant from a donor
• People who have a known allergy to any ingredient in the study drug
• People with interstitial lung disease (a condition causing scarring or inflammation in the lungs)
• People with other serious medical conditions that are not well controlled
• People with other significant illness, mental health conditions, or abnormal test results that the trial doctors believe could affect safety or the accuracy of trial results

Important: Always verify eligibility with the trial site directly before applying.